March 26, 2019 : DCMS #442

TOP STORIES — Diabetes News and Research

Fasting Glucose Estimates Absolute Risk for CVD

First Dual SGLT-1/2 Inhibitor For Adults With Type 1 Declined Approval

New FDA Extension for Farxiga and Xigduo XR

EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners

Paula Trief on Partners of Patients with Diabetes

CLINICAL GEMS — The Best from Diabetes Texts

International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #170: Molecular Genetics of Type 1 Diabetes Part 7

MOST POPULAR ARTICLES OF THE MONTH

#1 Aiming for an Ideal Exercise Blood Glucose
#2 Carbs Content Alone Not Enough for Insulin Calculations
#3 Benefits of Non-Sugar Sweeteners and Health Outcomes: Conflicting

Sometimes our obsession with clinically proven data can get in the way of patient care. We can see that this week in an article about the official indication for the dual SGLT-1/2 inhibitor sotagliflozin. To find out what our patients may end up missing, check out our article #2.

Dave Joffe

Editor-in-chief

Monitoring glucose in midlife may help prevent future cardiovascular disease, according to a study published in Diabetes Care.

Sanofi and Lexicon to continue any required studies in effort to move sotagliflozin forward.

Dapagliflozin’s updated package insert confirms efficacy and safety profile for patients with moderate chronic kidney disease.

Paula Trief, PhD received her PhD in Clinical Psychology from Syracuse University. She joined the faculty at SUNY Upstate Medical University in the Department of Psychiatry & Behavioral Sciences in 1993. She is currently a tenured Distinguished Service Professor of Psychiatry & Behavioral Sciences, with joint appointments in the departments of Medicine and Orthopedic Surgery. Academically, she is an active behavioral science researcher, studying behavioral interventions for patients with diabetes. Her current RO1 studies factors that predict medication adherence and healthcare usage in emerging adults with type 2 diabetes.

Clinical utility of T1DM susceptibility genes: One of the goals of genetic studies of complex disease is to identify a profile of susceptibility variants that can be used to predict an individual’s risk of developing a given disease. The long prodrome for T1DM, characterized by progressive loss of beta-cell mass, provides an attractive opportunity for intervention to prevent disease development if “at-risk” individuals can be identified. Currently the best markers of disease risk are a positive family history of T1DM and the presence of autoantibodies to islet cell proteins. Over 90% of T1DM patients have no affected relatives, however, so effective preventive efforts will need to target the general population. Unfortunately screening such huge numbers of individuals for islet autoantibodies is logistically unfeasible, particularly given the need for repeated annual testing for those with a negative result. Genetic markers are therefore needed to stratify risk in the general population,

By Sheri R. Colberg, PhD, FACSM

There is no official ideal blood glucose range to start with and maintain during physical activity, but we do know that being too low negatively impacts performance, as does being too high. As for what blood glucose target or range most athletes aim for, it depends on a number of factors, including the type, intensity, and duration of their activity. A consensus statement about exercise and type 1 diabetes published in The Lancet in 2017 suggested that a reasonable target for most people doing aerobic exercise lasting up to an hour is 126 to 180 mg/dL (7.0 to 10.0 mmol/L), only aiming higher for added protection against lows in some situations.

New evidence suggests added consideration of the protein and fat.

While increased cancer risk was not found, overall study of sweeteners vs sugar remains inconclusive.